skip to main content
Show Results with:

8 results  for Everything in this catalogue

Result Number Material Type Add to My Shelf Action Record Details and Options
1
Material Type:
Article
Add to My workspace

Synergistic antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 when combined with anti-PD-1 in murine tumor models

Murali, Addepalli et al.

Journal for immunotherapy of cancer. Volume 3:Issue 2 (2015); pp 1-2 -- BioMed Central

Online access

2
Material Type:
Article
Add to My workspace

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer

Adkins, Chris et al.

BMC cancer. Volume 15:Issue 1 (2015); pp 1-11 -- BioMed Central

Online access

3
Material Type:
Article
Add to My workspace

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

Twelves, Chris et al.

European journal of cancer -- Elsevier -- Volume: 76 C; (pages 205-215) -- 2017

Online access

4
Material Type:
Article
Add to My workspace

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Perez, Edith A et al.

The Lancet oncology. Volume 16:Issue 15 (2015); pp 1556-1568 -- Elsevier Science

Online access

5
Material Type:
Article
Add to My workspace

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Perez, Edith A et al.

The Lancet oncology. Volume 16:Issue 15 (2015); pp 1556-1568 -- Elsevier Science

Online access

6
Material Type:
Article
Add to My workspace

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

Twelves, Chris et al.

European journal of cancer. Volume 76 (2017); pp 205-215 -- Elsevier

Online access

7
Material Type:
Article
Add to My workspace

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Ager, Casey et al.

Journal for immunotherapy of cancer. Volume 4:Issue 1 (2016); pp 107-221 -- BioMed Central

Online access

8
Material Type:
Article
Add to My workspace

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Ager, Casey et al.

Journal for immunotherapy of cancer. Volume 4:Issue 1 (2016); pp 107-221 -- BioMed Central

Online access

8 results  for Everything in this catalogue

Refine Search Results

Creation date 

From To

Additional Features 

  1. Abstract  (5)
  2. No Abstract  (3)
  3. Refine further open sub menu

Searching Remote Databases, Please Wait